In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 3 ( 2022-3-30), p. e0264157-
Abstract:
The use of holding regimens for people living with HIV (PLWH) without effective antiretroviral options can have effects on outcomes and future treatment options. We aimed to investigate the use of holding regimens for PLWH in Asian countries. Data from adults enrolled in routine HIV care in IeDEA Asia-Pacific cohorts were included. Individuals were considered to be on holding regimen if they had been on combination antiretroviral therapy for at least 6 months, had two confirmed viral loads (VL) ≥1000 copies/mL, and had remained on the same medications for at least 6 months. Survival time was analyzed using Fine and Gray’s competing risk regression. Factors associated with CD4 changes and VL 〈 1000 copies/mL were analyzed using linear regression and logistic regression, respectively. A total of 425 PLWH (72.9% male; 45.2% high-income and 54.8% low-to-middle-income country) met criteria for being on a holding regimen. From high-income countries, 63.0% were on protease inhibitors (PIs); from low-to-middle-income countries, 58.4% were on non-nucleoside reverse transcriptase inhibitors (NNRTIs); overall, 4.5% were on integrase inhibitors. The combination of lamivudine, zidovudine, and efavirenz was the most commonly used single regimen (n = 46, 10.8%), followed by lamivudine, zidovudine, and nevirapine (n = 37, 8.7%). Forty-one PLWH (9.7%) died during follow-up (mortality rate 2.0 per 100 person-years). Age 〉 50 years compared to age 31–40 years (sub-hazard ratio [SHR] 3.29, 95% CI 1.45–7.43, p = 0.004), and VL ≥1000 copies/ml compared to VL 〈 1000 copies/mL (SHR, 2.14, 95% CI 1.08–4.25, p = 0.029) were associated with increased mortality, while higher CD4 counts were protective. In our Asia regional cohort, there was a diversity of holding regimens, and the patterns of PI vs. NNRTI use differed by country income levels. Considering the high mortality rate of PLWH with holding regimen, efforts to extend accessibility to additional antiretroviral options are needed in our region.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0264157
DOI:
10.1371/journal.pone.0264157.g001
DOI:
10.1371/journal.pone.0264157.g002
DOI:
10.1371/journal.pone.0264157.g003
DOI:
10.1371/journal.pone.0264157.t001
DOI:
10.1371/journal.pone.0264157.t002
DOI:
10.1371/journal.pone.0264157.t003
DOI:
10.1371/journal.pone.0264157.t004
DOI:
10.1371/journal.pone.0264157.s001
DOI:
10.1371/journal.pone.0264157.s002
DOI:
10.1371/journal.pone.0264157.s003
DOI:
10.1371/journal.pone.0264157.s004
DOI:
10.1371/journal.pone.0264157.r001
DOI:
10.1371/journal.pone.0264157.r002
DOI:
10.1371/journal.pone.0264157.r003
DOI:
10.1371/journal.pone.0264157.r004
DOI:
10.1371/journal.pone.0264157.r005
DOI:
10.1371/journal.pone.0264157.r006
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3